Analysis of Ebola virus and VLP release using an immunocapture assay

Journal of Virological Methods

Volumn 127, Issue 1, 2005, Pages 1-9

  Kallstrom, George ^a   Warfield, Kelly L ^a   Swenson, Dana L ^a   Mort, Shannon ^a   Panchal, Rekha G ^b   Ruthel, Gordon ^a   Bavari, Sina ^a   Aman, M Javad ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Diagnostic; Ebola; ELISA; Filovirus; NP; VLP; VP40

Indexed keywords

NUCLEOCAPSID PROTEIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; SCREENING TEST; VACCINATION; VALIDATION PROCESS; VIRUS CULTURE; VIRUS DETECTION; VIRUS PARTICLE;

ANIMALS; CELL LINE; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; NUCLEOCAPSID PROTEINS; NUCLEOPROTEINS; TRANSFECTION; VIRAL CORE PROTEINS;

EBOLA VIRUS; MARBURG-LIKE VIRUSES;

EID: 18944407310     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2005.02.015     Document Type: Article

References (30)

1. M.J. Aman, C.M. Bosio, R.G. Panchal, J.C. Burnett, A. Schmaljohn, and S. Bavari Molecular mechanisms of filovirus cellular trafficking Microbes Infect. 5 7 2003 639 649
2. C.F. Basler, X. Wang, E. Muhlberger, V. Volchkov, J. Paragas, H.D. Klenk, A. Garcia-Sastre, and P. Palese The Ebola virus VP35 protein functions as a type I IFN antagonist Proc. Natl. Acad. Sci. U.S.A. 97 22 2000 12289 12294
3. S. Bavari, C.M. Bosio, E. Wiegand, G. Ruthel, A.B. Will, T.W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn, and M.J. Aman Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses J. Exp. Med. 195 5 2002 593 602
4. A. Dessen, V. Volchkov, O. Dolnik, H.D. Klenk, and W. Weissenhorn Crystal structure of the matrix protein VP40 from Ebola virus Embo J. 19 16 2000 4228 4236
5. H. Feldmann, S. Jones, H.D. Klenk, and H.J. Schnittler Ebola virus: from discovery to vaccine Nat. Rev. Immunol. 3 8 2003 677 685
6. H. Feldmann, and M.P. Kiley Classification, structure, and replication of filoviruses Curr. Top. Microbiol. Immunol. 235 1999 1 21
7. H. Feldmann, and H.D. Klenk Marburg and Ebola viruses Adv. Virus Res. 47 1996 1 52
8. E.O. Freed Viral late domains J. Virol. 76 10 2002 4679 4687
9. H. Garoff, R. Hewson, and D.J. Opstelten Virus maturation by budding Microbiol. Mol. Biol. Rev. 62 4 1998 1171 1190
10. A. Groseth, H. Feldmann, S. Theriault, G. Mehmetoglu, and R. Flick RNA polymerase I-driven minigenome system for Ebola virus J. Virol. 79 2005 4425 4433
11. M. Hevey, D. Negley, J. Geisbert, P. Jahrling, and A. Schmaljohn Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants Virology 239 1 1997 206 216
12. M. Hevey, D. Negley, P. Pushko, J. Smith, and A. Schmaljohn Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates Virology 251 1 1998 28 37
13. Y. Huang, L. Xu, Y. Sun, and G.J. Nabel The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein Mol. Cells 10 2 2002 307 316
14. L.D. Jasenosky, G. Neumann, I. Lukashevich, and Y. Kawaoka Ebola virus VP40-induced particle formation and association with the lipid bilayer J. Virol. 75 11 2001 5205 5214
15. J.M. Licata, R.F. Johnson, Z. Han, and R.N. Harty Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles J. Virol. 78 14 2004 7344 7351
16. J.M. Licata, M. Simpson-Holley, N.T. Wright, Z. Han, J. Paragas, and R.N. Harty Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4 J. Virol. 77 3 2003 1812 1819
17. T. Noda, H. Sagara, E. Suzuki, A. Takada, H. Kida, and Y. Kawaoka Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP J. Virol. 76 10 2002 4855 4865
18. R.G. Panchal, G. Ruthel, T.A. Kenny, G.H. Kallstrom, D. Lane, S.S. Badie, L. Li, S. Bavari, and M.J. Aman In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding Proc. Natl. Acad. Sci. U.S.A. 100 26 2003 15936 15941
19. S. Scianimanico, G. Schoehn, J. Timmins, R.H. Ruigrok, H.D. Klenk, and W. Weissenhorn Membrane association induces a conformational change in the Ebola virus matrix protein Embo J. 19 24 2000 6732 6741
20. N.J. Sullivan, T.W. Geisbert, J.B. Geisbert, L. Xu, Z.Y. Yang, M. Roederer, R.A. Koup, P.B. Jahrling, and G.J. Nabel Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates Nature 424 6949 2003 681 684
21. N.J. Sullivan, A. Sanchez, P.E. Rollin, Z.Y. Yang, and G.J. Nabel Development of a preventive vaccine for Ebola virus infection in primates Nature 408 6812 2000 605 609
22. D.L. Swenson, K.L. Warfield, K. Kuehl, T. Larsen, M.C. Hevey, A. Schmaljohn, S. Bavari, and M.J. Aman Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein(1) FEMS Immunol. Med. Microbiol. 40 1 2004 27 31
23. J. Timmins, S. Scianimanico, G. Schoehn, and W. Weissenhorn Vesicular release of Ebola virus matrix protein VP40 Virology 283 1 2001 1 6
24. L. Vanderzanden, M. Bray, D. Fuller, T. Roberts, D. Custer, K. Spik, P. Jahrling, J. Huggins, A. Schmaljohn, and C. Schmaljohn DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge Virology 246 1 1998 134 144
25. K.L. Warfield, C.M. Bosio, B.C. Welcher, E.M. Deal, M. Mohamadzadeh, A. Schmaljohn, M.J. Aman, and S. Bavari Ebola virus-like particles protect from lethal Ebola virus infection Proc. Natl. Acad. Sci. U.S.A. 100 26 2003 15889 15894
26. K.L. Warfield, J.G. Perkins, D.L. Swenson, E.M. Deal, C.M. Bosio, M.J. Aman, W.M. Yokoyama, H.A. Young, and S. Bavari Role of natural killer cells in innate protection against lethal Ebola virus infection J. Exp. Med. 200 2 2004 169 179
27. K.L. Warfield, D.L. Swenson, D.L. Negely, A. Schmaljohn, M.J. Aman, and S. Bavari Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection Vaccine 22 25-26 2004 2495 2502
28. S. Watanabe, T. Watanabe, T. Noda, A. Takada, H. Feldmann, L.D. Jasenosky, and Y. Kawaoka Production of novel Ebola virus-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics J. Virol. 78 2 2004 999 1005
29. J.A. Wilson, M. Bray, R. Bakken, and M.K. Hart Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins Virology 286 2 2001 384 390
30. J.A. Wilson, and M.K. Hart Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein J. Virol. 75 6 2001 2660 2664